{'52WeekChange': 5.566038,
 'SandP52WeekChange': 0.0644362,
 'address1': '850 Maude Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 54.17,
 'askSize': 900,
 'averageDailyVolume10Day': 478700,
 'averageVolume': 727477,
 'averageVolume10days': 478700,
 'beta': 2.018487,
 'beta3Year': None,
 'bid': 41,
 'bidSize': 1200,
 'bookValue': 0.974,
 'category': None,
 'circulatingSupply': None,
 'city': 'Mountain View',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 53.784,
 'dayLow': 51.31,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -45.601,
 'enterpriseToRevenue': 90.834,
 'enterpriseValue': 3071014656,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 210 2910',
 'fiftyDayAverage': 58.223713,
 'fiftyTwoWeekHigh': 65.43,
 'fiftyTwoWeekLow': 6.16,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43031838,
 'forwardEps': -1.31,
 'forwardPE': -39.847332,
 'fromCurrency': None,
 'fullTimeEmployees': 82,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.28927,
 'heldPercentInstitutions': 0.67078,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/chemocentryx.com',
 'longBusinessSummary': 'ChemoCentryx, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of new medications for '
                        'inflammatory disorders, autoimmune diseases, and '
                        'cancer in the United States. Its lead drug candidate '
                        'is Avacopan, an orally-administered complement '
                        'inhibitor of the complement C5a receptor (C5aR), '
                        'which is in Phase III development for the treatment '
                        'of anti-neutrophil cytoplasmic '
                        'auto-antibody-associated vasculitis; and Phase IIb '
                        'clinical trial, the AURORA trial for the treatment of '
                        'patients with moderate-to-severe hidradenitis '
                        'suppurativa, as well as patients with complement 3 '
                        'glomerulopathy. In addition, the company is '
                        'developing CCX140, an inhibitor of the chemokine '
                        'receptor known as CCR2, which has completed a Phase '
                        'II clinical trial in diabetic nephropathy and is '
                        'being developed for patients with focal segmental '
                        'glomerulosclerosis; CCX507, a second generation CCR9 '
                        'inhibitor, which has completed Phase I clinical '
                        'trial; and CCX872, a potent and selective inhibitor '
                        'of CCR2, which is in phase Ib clinical trial for the '
                        'treatment of patients with stage 3 and 4 pancreatic '
                        'cancer. ChemoCentryx, Inc. was founded in 1996 and is '
                        'headquartered in Mountain View, California.',
 'longName': 'ChemoCentryx, Inc.',
 'market': 'us_market',
 'marketCap': 3540934912,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1001491',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -65227000,
 'nextFiscalYearEnd': 1640908800,
 'open': 52.92,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 210 2900',
 'previousClose': 53.5,
 'priceHint': 2,
 'priceToBook': 53.59343,
 'priceToSalesTrailing12Months': 104.7335,
 'profitMargins': -1.9292799,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 53.784,
 'regularMarketDayLow': 51.31,
 'regularMarketOpen': 52.92,
 'regularMarketPreviousClose': 53.5,
 'regularMarketPrice': 52.92,
 'regularMarketVolume': 374432,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 67834000,
 'sharesPercentSharesOut': 0.077800006,
 'sharesShort': 5275641,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3794024,
 'shortName': 'ChemoCentryx, Inc.',
 'shortPercentOfFloat': 0.1163,
 'shortRatio': 5.54,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CCXI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.108,
 'twoHundredDayAverage': 49.826977,
 'volume': 374432,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.chemocentryx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94043'}